Chemours Q1 2023 net sales $1.5B, adj EBITDA $304M; reaffirms FY guidance

Chemours Co

2023-Q1 EPS reported $0.96 revenue$1,536,000,000

Net sales $1.5B, down 13% YoY; Net income $145M, EPS $0.96; Adjusted EPS $0.98, down 33%.
Adjusted EBITDA $304M, down 25% YoY; TSS segment record results on Opteon demand; TT mixed.
Board approved Q2 dividend of $0.25 per share, unchanged from prior quarter.
Appointed Denise Dignam President, TT & Chemical Solutions; Gerardo Familiar President, APM.
Reaffirming full-year 2023 Adjusted EBITDA and Free Cash Flow guidance.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Chemours Co reported first quarter 2023 results: revenue $1.5 billion, net income $145 million, EPS $0.96. Guidance reaffirmed.

Period: first quarter 2023
Revenue: $1.5 billion
Net income: $145 million
EPS: $0.96
Guidance: reaffirmed
Result: reported results

Exact text from the filing

The Chemours Company Reports First Quarter 2023 Results Strong first quarter in Thermal & Specialized Solutions, company reaffirming full year 2023 Adjusted EBITDA and Free Cash Flow guidance Wilmington, Del ., April 27, 2023 -- The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (TT), Thermal & Specialized Solutions (TSS), and Advanced Performance Materials (APM), today announced its financial results for the first quarter 2023. First Quarter 2023 Results & Highlights • Net Sales of $1.5 billion • Net Income of $145 million with EPS 1 of $0.96

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Chemours Co filing history →

Source: SEC EDGAR

accession 0000950170-23-015291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.